Medpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback
On October 21, Medpace reported third-quarter 2026 revenue of $716.0 million, up 8.5% year over year, with net income of $137.5 million and diluted EPS of $4.84. EBITDA increased 16.0% to $172.1 million, while net new business awards rose 10.6% year over year to $873.4 million. The board replaced its existing repurchase authorization with a new program allowing up to $1 billion in buybacks, and Medpace raised or reaffirmed its 2026 outlook at $2.835 billion to $2.855 billion of revenue and $17.97 to $18.32 of diluted EPS.
Why it matters
The results provide investors with stronger quarterly profitability and bookings momentum, while the $1 billion authorization creates additional potential demand for Medpace shares. The 2026 revenue and EPS ranges set the company’s near-term financial framework, and the authorization replaces the prior program effective October 20, 2026.
Key facts
- 1Third-quarter 2026 revenue increased 8.5% year over year to $716.0 million, and GAAP net income was $137.5 million, or $4.84 per diluted share. stocktitan.net
- 2Third-quarter EBITDA rose 16.0% year over year to $172.1 million, producing an EBITDA margin of 24.0%. stocktitan.net
- 3Net new business awards increased 10.6% year over year to $873.4 million in the third quarter of 2026. stocktitan.net
- 4The board approved repurchases of up to $1 billion effective October 20, 2026, after terminating the existing authorization. finance.yahoo.com
- 5Medpace expects 2026 revenue of $2.835 billion to $2.855 billion, EBITDA of $638 million to $652 million, net income of $514 million to $524 million, and diluted EPS of $17.97 to $18.32. finance.yahoo.com
Open questions
- Material 6 describes 2026 EPS guidance as $18.15, while materials 10, 14 and 15 report a range of $17.97 to $18.32; the relationship between the single figure and the reported range is not specified.
Summary written by AlphAI AI Desk from 16 of 16 sources. Not investment advice. Figures are as stated by the linked sources.